Table 4.
Comparison of clinical and treatment outcomes in the propensity-matched score cohorts.
| Variable | Initially intravenous infliximab (IVi group) (N = 121) | Initially subcutaneous anti-TNF (SCi group) (N = 121) | p |
|---|---|---|---|
| Clinical response at week 14 (%) | 35 | 50 | 0.019 |
| Clinical remission at week 14 (%) | 19 | 29 | 0.097 |
| Clinical response at week 52 (%) | 33 | 42 | 0.138 |
| Clinical remission at week 2 (%) | 27 | 33 | 0.315 |
| Secondary loss of response to the second anti-TNF (%) | 29 | 34 | 0.489 |
| Time to dose escalation (months), median (range interval) | 17.5 (25.4) | 20.7 (19.9) | 0.854 |
| Treatment persistence (months), median (range interval) | 217.1 (247.7) | 170 (125) | 0.064 |
Bold and italic characters within the Tables are used to highlight statistically significant results.